There are currently 1053 clinical trials in Aurora, Colorado looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Hospital Colorado, University of Colorado, University of Colorado Hospital and University of Colorado- Denver. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
NCT05206513
Recruiting
The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in pediatric and adult participants who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.
Gender:
All
Ages:
Between 6 years and 70 years
Trial Updated:
06/20/2024
Locations: Neurocrine Clinical Site, Aurora, Colorado
Conditions: Dyskinesia, Cerebral Palsy
Register for Updates
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)
NCT05063162
Recruiting
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
06/20/2024
Locations: Mog001 50101, Aurora, Colorado
Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
Register for Updates
Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes
NCT06273124
Recruiting
The purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS). Participants will be asked to: Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL for one hour
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/20/2024
Locations: Barbara Davis Center, Aurora, Colorado
Conditions: Type1diabetes
Register for Updates
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
NCT06280391
Recruiting
ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study is to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive). Study details include: The study duration (screening, 24-52-week treatment, 20-week safety follow-up) will be up to 47-77 weeks. The... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/20/2024
Locations: Allianz Research Institute CO Site Number : 8400038, Aurora, Colorado
Conditions: Bronchiectasis
Register for Updates
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT05171075
Recruiting
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates
Bone, Exercise, Alendronate, and Caloric Restriction
NCT05764733
Recruiting
The purpose of this research is to identify strategies that minimize bone loss that occurs when older adults lose weight. Participation in this research will involve up to nine assessment visits and last up to two years.
Gender:
All
Ages:
60 years and above
Trial Updated:
06/20/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Bone Loss
Register for Updates
Pediatric Prehospital Airway Resuscitation Trial
NCT06364280
Recruiting
This study is a Phase 3, multi-center, Bayesian Adaptive Sequential Platform Trial testing the effectiveness of different prehospital airway management strategies in the care of critically ill children. Emergency Medical Services (EMS) agencies affiliated with the Pediatric Emergency Care Applied Research Network (PECARN) will participate in the trial. The study interventions are strategies of prehospital airway management: [BVM-only], [BVM followed by SGA] and [BVM followed by ETI]. The primary... Read More
Gender:
All
Ages:
Between 24 hours and 17 years
Trial Updated:
06/20/2024
Locations: University of Colordao, Aurora, Colorado
Conditions: Heart Arrest, Out-Of-Hospital, Wounds and Injuries, Respiratory Insufficiency in Children, Child, Only, Critical Illness
Register for Updates
A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)
NCT04796337
Recruiting
This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept (MK-7962, formerly called ACE-011) in participants with Pulmonary Arterial Hypertension (PAH). This open-label, long-term follow-up (LTFU) study is supported by data from the PULSAR study (Phase 2, NCT03496207) in which treatment with sotatercept resulted in hemodynamic and functional improvements in the study participants, including those receiving maximal PAH therapy with double/triple drug... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: University of Colorado Hospital ( Site 1013), Aurora, Colorado
Conditions: PAH, Pulmonary Arterial Hypertension
Register for Updates
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049
Recruiting
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267
Recruiting
The primary objective of the study is to demonstrate the efficacy of high dose and low dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To evaluate the efficacy of Fp/ABS compared to ABS and the effect on systemic corticosteroid (SCS) exposure To evaluate the safety and tolerability of Fp/A BS The duration for each part... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
06/20/2024
Locations: Teva Investigational Site 15612, Aurora, Colorado
Conditions: Asthma
Register for Updates
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085
Recruiting
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16. The primary hypothesis is Vericiguat is superior to placebo in reducing NT-proBNP at Week 16.
Gender:
All
Ages:
Between 29 days and 17 years
Trial Updated:
06/20/2024
Locations: Children's Hospital Colorado ( Site 0012), Aurora, Colorado
Conditions: Heart Failure, Left Ventricular Systolic Dysfunction
Register for Updates
MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756
Recruiting
This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of MK-0616, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of MK-0616 compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular, Aurora, Colorado
Conditions: Arteriosclerosis, Hypercholesterolaemia
Register for Updates